Health
Recce Pharmaceuticals” R327 demonstrates positive efficacy against ‘flesh-eating” bacteria – Proactive Investors Australia
RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours,…

RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), a company developing new classes of synthetic anti-infectives,…
Continue Reading